Risk factors of paclitaxel-induced peripheral neuropathy in patients with breast cancer: a prospective cohort study
Abstract
Objective Chemotherapy-induced peripheral neuropathy (CIPN) is a common and severe adverse reaction in taxane-based chemotherapy. This study aimed to analyze the risk factors of peripheral neuropathy in patients with breast cancer receiving paclitaxel chemotherapy to provide a reference for the early prevention of CIPN. Methods We included 350 patients with breast cancer who received chemotherapy for the first time at the Tangshan People’s Hospital between August 2022 and June 2023 and were followed for at least 3 months after the end of chemotherapy. The incidence of CIPN in patients with breast cancer was calculated, and risk factors for CIPN were analyzed using logistic regression analysis. Results The incidence rate of CIPN was 79.1%. Multifactor logistic regression analysis indicated that age ≥45 years [odds ratio (OR)=5.119, 95% confidence interval (CI)=1.395–18.780] and ≥60 years (OR=9.366, 95% CI=1.228–71.421), history of hypertension (OR=3.475, 95% CI=1.073–11.250), cumulative dose of chemotherapy drugs >900 mg (OR=4.842, 95% CI=1.961–5.946), vitamin D deficiency (OR=6.214, 95% CI=2.308–16.729), abnormal alanine aminotransferase (OR=3.154, 95% CI=1.010–9.844), anemia before chemotherapy (OR=2.770, 95% CI=1.093–7.019), infusion duration of chemotherapy drugs >30 min (OR=3.673, 95% CI=1.414–9.539), body mass index ≥24 kg/m2 (OR=8.139, 95% CI=1.157–57.240), mild depression (OR=4.546, 95% CI=1.358–15.223), and major depression (OR=4.455, 95% CI=1.237–16.037) increased…
How strong is the evidence?
Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 350 participants or records.
Read the paper
Related studies
- Ferulic acid regulates the AKT/GSK-3β/CRMP-2 signaling pathway in a middle cerebral artery occlusion animal model
- Novel Pharmacokinetic/Pharmacodynamic Parameters Quantify the Exposure–Effect Relationship of Levofloxacin against Fluoroquinolone-Resistant Escherichia coli
- Photochemical behavior of levofloxacin
- Correlation Between Dissolution Profiles of Salt-Form Drugs in Biorelevant Bicarbonate Buffer and Oral Drug Absorption: Importance of Dose/ Fluid Volume Ratio
- Evaluation of the synergistic potential and mechanisms of action for de novo designed cationic antimicrobial peptides
- Synthesis of [11C]levofloxacin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.